Related Experiment Video
Updated: Mar 26, 2026
Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma
Published on: September 8, 2021
Braf V600E mutation in melanoma: translational current scenario
J A Guadarrama-Orozco1, A Ortega-Gómez1, E B Ruiz-García2
1Translational Medicine Laboratory, National Cancer Institute, San Fernando N.22, CP 14080, Mexico City, Mexico.
Abstract:
Melanoma was one of the translational cancer examples in clinic, including target therapy related to specific biomarkers impacting in the outcome of melanoma patients. Melanomagenesis involved a wide variety of mutations during his evolution; many of these mutated proteins have a kinase activity. One of the most cited proteins in melanoma is BRAF (about 50-60 % of melanomas harbors activating BRAF mutations), for these the most common is a substitution of valine to glutamic acid at codon 600 (p.V600E). Therefore, the precise identification of this underlying somatic mutation is essential; knowing the translational implications has opened a wide view of melanoma biology and therapy.
Insights
Identifying the BRAF p.V600E mutation is crucial for melanoma treatment. This specific mutation impacts patient outcomes and guides targeted therapy development in melanoma.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Melanoma exhibits significant genetic evolution with numerous mutations.
- Many mutated proteins in melanoma possess kinase activity, influencing cancer progression.
- BRAF mutations are prevalent, found in 50-60% of melanoma cases.
Purpose of the Study:
- To highlight the importance of precise identification of BRAF mutations in melanoma.
- To underscore the translational implications of understanding BRAF mutations for patient therapy.
- To emphasize the role of specific biomarkers in melanoma treatment outcomes.
Main Methods:
- Analysis of somatic mutations in melanoma.
- Focus on kinase activity of mutated proteins.
- Identification of the BRAF gene and its common mutations.
Main Results:
- The BRAF gene is frequently mutated in melanoma, with the p.V600E substitution being the most common.
- Precise identification of the BRAF p.V600E mutation is essential for clinical management.
- Understanding these mutations provides insights into melanoma biology.
Conclusions:
- Targeted therapies based on specific biomarkers, like BRAF mutations, are vital for melanoma treatment.
- Accurate molecular diagnosis is key to effective melanoma patient management.
- BRAF mutation status significantly impacts therapeutic strategies and patient outcomes.
More Related Videos
Related Concept Videos
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
01:20The Retinoblastoma Gene